200 related articles for article (PubMed ID: 21080797)
21. [Ipilimumab treatment of metastatic melanoma].
Ghasemi H; Schmidt H; Stolle LB
Ugeskr Laeger; 2015 Jan; 177(2A):108-9. PubMed ID: 25612993
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
23. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
Wolchok JD; Neyns B; Linette G; Negrier S; Lutzky J; Thomas L; Waterfield W; Schadendorf D; Smylie M; Guthrie T; Grob JJ; Chesney J; Chin K; Chen K; Hoos A; O'Day SJ; Lebbé C
Lancet Oncol; 2010 Feb; 11(2):155-64. PubMed ID: 20004617
[TBL] [Abstract][Full Text] [Related]
24. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
Johnson DB; Sullivan RJ; Ott PA; Carlino MS; Khushalani NI; Ye F; Guminski A; Puzanov I; Lawrence DP; Buchbinder EI; Mudigonda T; Spencer K; Bender C; Lee J; Kaufman HL; Menzies AM; Hassel JC; Mehnert JM; Sosman JA; Long GV; Clark JI
JAMA Oncol; 2016 Feb; 2(2):234-40. PubMed ID: 26633184
[TBL] [Abstract][Full Text] [Related]
25. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Simeone E; Gentilcore G; Giannarelli D; Grimaldi AM; Caracò C; Curvietto M; Esposito A; Paone M; Palla M; Cavalcanti E; Sandomenico F; Petrillo A; Botti G; Fulciniti F; Palmieri G; Queirolo P; Marchetti P; Ferraresi V; Rinaldi G; Pistillo MP; Ciliberto G; Mozzillo N; Ascierto PA
Cancer Immunol Immunother; 2014 Jul; 63(7):675-83. PubMed ID: 24695951
[TBL] [Abstract][Full Text] [Related]
26. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
27. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
[TBL] [Abstract][Full Text] [Related]
28. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
29. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
30. Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
Letendre P; Monga V; Milhem M; Zakharia Y
Future Oncol; 2017 Mar; 13(7):625-636. PubMed ID: 27882779
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulatory therapy for melanoma: ipilimumab and beyond.
Callahan MK; Postow MA; Wolchok JD
Clin Dermatol; 2013; 31(2):191-9. PubMed ID: 23438382
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
33. Ipilimumab approved for metastatic melanoma.
Traynor K
Am J Health Syst Pharm; 2011 May; 68(9):768. PubMed ID: 21515855
[No Abstract] [Full Text] [Related]
34. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
35. Ipilimumab for metastatic melanoma.
Ozao-Choy J; Carvajal RD; Hamid O
Drugs Today (Barc); 2012 Jun; 48(6):381-93. PubMed ID: 22745924
[TBL] [Abstract][Full Text] [Related]
36. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Bastholt L; Mortier L; Thomas L; Tahir S; Hauschild A; Hassel JC; Hodi FS; Taitt C; de Pril V; de Schaetzen G; Suciu S; Testori A
N Engl J Med; 2016 Nov; 375(19):1845-1855. PubMed ID: 27717298
[TBL] [Abstract][Full Text] [Related]
37. Ipilimumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2012 Dec; 12(12):1511-21. PubMed ID: 23181437
[TBL] [Abstract][Full Text] [Related]
38. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
39. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
[TBL] [Abstract][Full Text] [Related]
40. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Hanaizi Z; van Zwieten-Boot B; Calvo G; Lopez AS; van Dartel M; Camarero J; Abadie E; Pignatti F
Eur J Cancer; 2012 Jan; 48(2):237-42. PubMed ID: 22030452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
